Everything below concerns actin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
| Property | Value | Notes |
|---|---|---|
| Purity determination | Reversed-phase HPLC | UV detection commonly at 214 nm |
| Mass confirmation | Mass spectrometry | Compared against theoretical 888.5 Da |
| Powder storage | -20 C or below | Dry and protected from light |
| Reconstituted storage | Aliquoted and frozen | Avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Sterile water or neutral buffer | Avoid extreme pH conditions |
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
== Acquisitions == In July 2016, Relief acquired FirstString Research, a clinical-stage biotech firm based in Charleston, South Carolina, US. In January 2021, Relief acquired German-based firm AdVita in a €25 million agreement to further their research into inhaled treatments for Acute respiratory distress syndrome. In May 2021, Relief acquired Swiss biotech firm Applied Pharma Research (APR), including its existing portfolio and all pipeline products, for CHF 72 million ($79 million).
=== Enzymatic biotinylation === In contrast to chemical biotinylation methods, enzymatic biotinylation allows biotin to be linked at exactly one residue present in the protein. This biotinylation reaction can also go to completion, meaning that the product is generated with high uniformity and can be linked to streptavidin in a defined orientation e.g. for MHC multimers. Enzymatic biotinylation is most often carried out by E. coli biotin holoenzyme synthetase, also known as biotin ligase (BirA, P06709). The most common way of targeting a protein of interest is by fusing the protein at its N-terminus, C-terminus or at an internal loop to a 15 amino acid peptide (GLNDIFEAQKIEWHE), termed AviTag or Acceptor Peptide (AP). Once tagged, the protein is then incubated with BirA allowing biotinylation to take place in the presence of biotin and ATP. Enzymatic biotinylation can be carried out in vitro but BirA also reacts specifically with its target peptide inside mammalian and bacterial cells and at the cell surface, while other cellular proteins are not modified. Enzymatic biotinylation can also take place in vivo typically through the co-expression of an Avitag tagged protein and BirA. The natural substrate of BirA is the biotin carboxyl carrier protein (BCCP). Before smaller tags were discovered, a protein needed to be fused to the entire BCCP to be targeted. A protein fused by BCCP can be recognized by biotin molecules in vivo and attach to it. A few other small tags have been used before AviTag, but AviTag is the most efficient so far.
== Functional features == Observations of limiting enzymatic hydrolysis elicited by trypsin in a controlled environment have shown an increase in hemp protein isolate (HSI) solubility at various pH and a notable decrease in the recorded emulsifying activity index.
The warfare grounded on certain uses of ICTs within an offensive or defensive military strategy endorsed by a state and aiming at the immediate disruption or control of the enemy's resources, and which is waged within the informational environment, with agents and targets ranging both on the physical and non-physical domains and whose level of violence may vary upon circumstances. Robinson et al. proposed in 2015 that the intent of the attacker dictates whether an attack is warfare or not, defining cyber warfare as "the use of cyber attacks with a warfare-like intent." In 2010, the former US National Coordinator for Security, Infrastructure Protection and Counter-terrorism, Richard A. Clarke, defined cyberwarfare as "actions by a nation-state to penetrate another nation's computers or networks for the purposes of causing damage or disruption". The target's own cyber-physical infrastructure may be used by the adversary in case of a cyber conflict, thus weaponizing it.
Sources: en.wikipedia.org
=== Temperature Modulated DSC === When performing Temperature Modulated DSC (TMDSC, MDSC), the underlying linear heating rate is superimposed by a sinusoidal temperature variation. The benefit of this procedure is the ability to separate overlapping DSC effects by calculating the reversing and the non-reversing signals. The reversing heat flow is related to the changes in specific heat capacity (→ glass transition) while the non-reversing heat flow corresponds to time-dependent phenomena such as curing, dehydration and relaxation.
== Death == Florey published his last scientific paper, co-written with Jennings, in 1967. He had written or co-written over two hundred papers. He died at his home at the provost's lodgings, of congestive heart failure on 21 February 1968. Although Florey was an agnostic, a funeral service was held in the St. Nicholas' parish church in Marston. A memorial plaque was placed on the outside wall near the entrance; the church refused to allow it to be placed inside because Florey had been so outspoken in his disbelief. A larger service at Westminster Abbey in London was attended by about 500 people. His remains were cremated.
Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008. It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell factor. It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E. coli. Because Ancestim is produced in E. coli, it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplantation in certain cancer patients.
{\displaystyle {\begin{array}{l}{}\\{\ce {^{235}_{92}U->[\alpha ][7.04\times 10^{8}\ {\ce {y}}]{^{231}_{90}Th}->[\beta ^{-}][25.52\ {\ce {h}}]{^{231}_{91}Pa}->[\alpha ][3.27\times 10^{4}\ {\ce {y}}]{^{227}_{89}Ac}}}{\begin{Bmatrix}{\ce {->[98.62\%\beta ^{-}][21.772\ {\ce {y}}]{^{227}_{90}Th}->[\alpha ][18.693\ {\ce {d}}]}}\\{\ce {->[1.38\%\alpha ][21.772\ {\ce {y}}]{^{223}_{87}Fr}->[\beta ^{-}][22.00\ {\ce {min}}]}}\end{Bmatrix}}{\ce {^{223}_{88}Ra->[\alpha ][11.435\ {\ce {d}}]{^{219}_{86}Rn}}}\\{\ce {^{219}_{86}Rn->[\alpha ][3.96\ {\ce {s}}]{^{215}_{84}Po}->[\alpha ][1.781\ {\ce {ms}}]{^{211}_{82}Pb}->[\beta ^{-}][36.16\ {\ce {min}}]{^{211}_{83}Bi}}}{\begin{Bmatrix}{\ce {->[99.724\%\alpha ][2.14\ {\ce {min}}]{^{207}_{81}Tl}->[\beta ^{-}][4.77\ {\ce {min}}]}}\\{\ce {->[0.276\%\beta ^{-}][2.14\ {\ce {min}}]{^{211}_{84}Po}->[\alpha ][0.516\ {\ce {s}}]}}\end{Bmatrix}}{\ce {^{207}_{82}Pb}}\end{array}}}
=== Damaging and overloading === If a lithium-ion battery is damaged, crushed, or subjected to a higher electrical load without having overcharge protection, problems may arise. External short circuit can trigger a battery explosion. Such incidents can occur when lithium-ion batteries are not disposed of through the appropriate channels, but are thrown away with other waste. The way they are treated by recycling companies can damage them and cause fires, which in turn can lead to large-scale conflagrations. Twelve such fires were recorded in Swiss recycling facilities in 2023. If overheated or overcharged, Li-ion batteries may suffer thermal runaway and cell rupture. During thermal runaway, internal degradation and oxidization processes can keep cell temperatures above 500 °C, with the possibility of igniting secondary combustibles, as well as leading to leakage, explosion or fire in extreme cases. To reduce these risks, many lithium-ion cells (and battery packs) contain fail-safe circuitry that disconnects the battery when its voltage is outside the safe range of 3–4.2 V per cell, or when overcharged or discharged. Lithium battery packs, whether constructed by a vendor or the end-user, without effective battery management circuits are susceptible to these issues. Poorly designed or implemented battery management circuits also may cause problems; it is difficult to be certain that any particular battery management circuitry is properly implemented.
Sources: en.wikipedia.org
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.
Mass spectrometry is the usual confirmatory method because it measures the intact mass. Reversed-phase chromatography is used alongside it to estimate purity.
Not directly. Reported percentages depend on the chromatographic method, detection wavelength, and integration criteria, so the underlying method details matter.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.